Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

INCLUSION CRITERIA Initial Presentation * Age between 18 and 70 years * ECOG 0 - 2 * Patients with histologically confirmed multiple myeloma with ≥ 30% bone * marrow involvement and a de novo presentation. One cycle of prior * chemotherapy for myeloma is allowed. Local radiation therapy is permitted * Ability to give informed consent * No existing secondary malignancies and no history of secondary malignancies in the past 5 years (other than a history of carcinoma in situ of the cervix, superficial skin cancer, or superficial bladder cancer) * No active autoimmune disease, nor a history of any autoimmune disease requiring medical treatment with systemic immunosuppressants * No corticosteroids within 28 days of tumor harvest * No major active medical or psychosocial problems that could be exacerbated or complicated by this treatment * Not pregnant * HIV negative * AST/ALT, total bilirubin \< threefold normal * Absolute neutrophil count \>500/mm3 * Platelet count \>30,000/mm3 Prior to Transplantation * ECOG performance status of 0 - 2. * No active/uncontrolled infection. * Absolute neutrophil count (ANC) \>1000/mm3. * Platelet count \>50,000/mm3. * Hemoglobin \>8g/dL * AST/ALT, total bilirubin \<3-fold normal. * 50% or greater reduction in tumor burden with prior chemotherapy * Patient has received a minimum of 2 cycles of an accepted induction * chemotherapy regimen * Patient fulfills the requirements for standard peripheral stem cell transplantation Prior to Posttransplant Vaccination * No active/uncontrolled infection * Absolute neutrophil count (ANC) \>1000/mm3 * Platelet count \>50,000/mm3 * Hemoglobin \>8g/dL * AST/ALT, total bilirubin \<3-fold normal * No unresolved Grade 3 or 4 adverse events related to the transplant EXCLUSION CRITERIA • Failure of autologous tumor-cell processing for vaccine production